Roderick A. Stegeman
Pharmacia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Roderick A. Stegeman.
Nature | 2000
James R. Kiefer; Jennifer L. Pawlitz; Kirby T. Moreland; Roderick A. Stegeman; William F. Hood; James K. Gierse; Anna M. Stevens; Douglas C. Goodwin; Scott W. Rowlinson; Lawrence J. Marnett; William C. Stallings; Ravi G. Kurumbail
Cyclooxygenases are bifunctional enzymes that catalyse the first committed step in the synthesis of prostaglandins, thromboxanes and other eicosanoids. The two known cyclooxygenases isoforms share a high degree of amino-acid sequence similarity, structural topology and an identical catalytic mechanism. Cyclooxygenase enzymes catalyse two sequential reactions in spatially distinct, but mechanistically coupled active sites. The initial cyclooxygenase reaction converts arachidonic acid (which is achiral) to prostaglandin G2 (which has five chiral centres). The subsequent peroxidase reaction reduces prostaglandin G2 to prostaglandin H2. Here we report the co-crystal structures of murine apo-cyclooxygenase-2 in complex with arachidonic acid and prostaglandin. These structures suggest the molecular basis for the stereospecificity of prostaglandin G2 synthesis.
Biochemistry | 2009
Li Xing; Huey Shieh; Shaun R. Selness; Rajesh Devraj; John K. Walker; Balekudru Devadas; Heidi R. Hope; Robert P. Compton; John F. Schindler; Jeffrey L. Hirsch; Alan G. Benson; Ravi G. Kurumbail; Roderick A. Stegeman; Jennifer M. Williams; Richard M. Broadus; Zara Walden; Joseph B. Monahan
PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS), first proposed by molecular modeling and subsequently confirmed by experiments. On the basis of structural comparison with a different biaryl pyrazole template and supported by dozens of high-resolution crystal structures of p38alpha inhibitor complexes, PH-797804 is predicted to possess a high level of specificity across the broad human kinase genome. We used a structural bioinformatics approach to identify two selectivity elements encoded by the TXXXG sequence motif on the p38alpha kinase hinge: (i) Thr106 that serves as the gatekeeper to the buried hydrophobic pocket occupied by 2,4-difluorophenyl of PH-797804 and (ii) the bidentate hydrogen bonds formed by the pyridinone moiety with the kinase hinge requiring an induced 180 degrees rotation of the Met109-Gly110 peptide bond. The peptide flip occurs in p38alpha kinase due to the critical glycine residue marked by its conformational flexibility. Kinome-wide sequence mining revealed rare presentation of the selectivity motif. Corroboratively, PH-797804 exhibited exceptionally high specificity against MAP kinases and the related kinases. No cross-reactivity was observed in large panels of kinase screens (selectivity ratio of >500-fold). In cellular assays, PH-797804 demonstrated superior potency and selectivity consistent with the biochemical measurements. PH-797804 has met safety criteria in human phase I studies and is under clinical development for several inflammatory conditions. Understanding the rationale for selectivity at the molecular level helps elucidate the biological function and design of specific p38alpha kinase inhibitors.
Bioorganic & Medicinal Chemistry Letters | 2000
Thomas E. Barta; Daniel P. Becker; Louis J. Bedell; Gary A. De Crescenzo; Joseph J. Mcdonald; Grace E. Munie; Shashi Rao; Huey-Sheng Shieh; Roderick A. Stegeman; Anna M. Stevens; Clara I. Villamil
A series of novel, MMP-1 sparing arylhydroxamate sulfonamides with activity against MMP-2 and -13 is described.
Bioorganic & Medicinal Chemistry Letters | 2003
Michael S. South; Brenda L. Case; Rhonda Wood; Darin E. Jones; Michael J. Hayes; Thomas J. Girard; Rhonda M. Lachance; Nancy S. Nicholson; Michael Clare; Anna M. Stevens; Roderick A. Stegeman; William C. Stallings; Ravi G. Kurumbail; John J. Parlow
Structure-based drug design coupled with polymer-assisted solution-phase library synthesis was utilized to develop a series of pyrazinone inhibitors of the tissue factor/Factor VIIa complex. The crystal structure of a tri-peptide ketothiazole complexed with TF/VIIa was utilized in a docking experiment that identified a benzyl-substituted pyrazinone as a P(2) surrogate for the tri-peptide. A 5-step PASP library synthesis of these aryl-substituted pyrazinones was developed. The sequence allows for attachment of a variety of P(1) and P(3) moieties, which led to synthesis pyrazinone 23. Compound 23 exhibited 16 nM IC(50) against TF/VIIa with >6250x selectivity versus Factor Xa and thrombin. This potent and highly selective inhibitor of TF/VIIa was chosen for pre-clinical intravenous proof-of-concept studies to demonstrate the separation between antithrombotic efficacy and bleeding side effects in a primate model of thrombosis.
Journal of Molecular Biology | 1989
Louis W. Lim; Roderick A. Stegeman; Nancy K. Leimgruber; James K. Gierse; Sherin S. Abdel-Meguid
Single crystals of glycosylated recombinant human renin have been obtained using the hanging-drop vapor diffusion method with polyethylene glycol and sodium chloride as coprecipitants. The crystals belong to the cubic space group P2(1)3 with a = 143.0 A and contain two molecules of renin in the asymmetric unit. A self-rotation function study using 5.5 A data shows the orientation of a non-crystallographic 2-fold axis relating these two monomers.
Bioorganic & Medicinal Chemistry Letters | 2003
Michael S. South; Thomas A Dice; Thomas J. Girard; Rhonda M. Lachance; Anna M. Stevens; Roderick A. Stegeman; William C. Stallings; Ravi G. Kurumbail; John J. Parlow
A solution-phase synthesis of an alpha-ketothiazole library of the general form D-Phe-L-AA-L-Arg-alpha-ketothiazole is described. The five-step synthesis is accomplished using a combination of polymeric reagents and polymer-assisted solution-phase purification protocols, including reactant-sequestering resins, reagent-sequestering resins, and tagged reagents. The multi-step synthesis affords the desired alpha-ketothiazole products in excellent purities and yields. A variety of L-amino acid inputs were used to probe the S2 pocket of the tissue factor (TF) VIIa enzyme to influence both potency and selectivity. An X-ray crystal structure of compound 10e bound to the TF/VIIa complex was obtained that explains the observed selectivity. The alpha-ketothiazoles were found to be potent, reversible-covalent inhibitors of tissue factor VIIa, with some analogues demonstrating selectivity versus thrombin.
Nature | 1996
Ravi G. Kurumbail; Anna M. Stevens; James K. Gierse; Joseph J. Mcdonald; Roderick A. Stegeman; Jina Y. Pak; Daniel Gildehaus; Julie M. Miyashiro; Thomas D. Penning; Karen Seibert; Peter C. Isakson; William C. Stallings
Nature | 1996
Huey-Sheng Shieh; Ravi G. Kurumbail; Anna M. Stevens; Roderick A. Stegeman; Eric J. Sturman; Jina Y. Pak; Arthur J. Wittwer; Mark O. Palmier; Roger C. Wiegand; Barry C. Holwerda; William C. Stallings
Journal of Medicinal Chemistry | 2003
John J. Parlow; Brenda L. Case; Thomas A. Dice; Ricky L. Fenton; Michael J. Hayes; Darin E. Jones; William L. Neumann; Rhonda Wood; Rhonda M. Lachance; Thomas J. Girard; Nancy S. Nicholson; Michael Clare; Roderick A. Stegeman; Anna M. Stevens; William C. Stallings; Ravi G. Kurumbail; Michael S. South
Journal of Medicinal Chemistry | 2003
John J. Parlow; Ravi G. Kurumbail; Roderick A. Stegeman; Anna M. Stevens; William C. Stallings; Michael S. South